Quarterly report pursuant to Section 13 or 15(d)

SEGMENT INFORMATION

v3.19.1
SEGMENT INFORMATION
3 Months Ended
Jan. 31, 2019
Segment Reporting [Abstract]  
Segment Reporting Disclosure [Text Block]

10.       SEGMENT INFORMATION          


We follow the accounting guidance of ASC 280 “Segment Reporting” (“ASC 280”).  Reportable operating segments are determined based on the management approach.  The management approach, as defined by ASC 280, is based on the way that the chief operating decision-maker organizes the segments within an enterprise for making operating decisions and assessing performance.  While our results of operations are primarily reviewed on a consolidated basis, the chief operating decision-maker manages the enterprise in three reportable segments, each with different operating and potential revenue generating characteristics: (i) development of our Cchek™ cancer detection platform, (ii) development of CAR-T therapeutics and (iii) our legacy patent licensing activities.  The following represents selected financial information for our segments for the three months ended January 31, 2019 and 2018 and as of  January 31, 2019 and October 31, 2018:


 

For the Three Months Ended

January 31,

 
 

2019

 

2018

Net loss:

 

 

 

 

 

Cchek™ cancer detection platform

$

(1,804,354)

 

$

(623,249)

CAR-T therapeutics

 

(2,487,285)

 

 

(1,109,018)

Patent licensing

 

(674,970)

 

 

(133,207)

 Total

$

(4,966,609)

 

$

(1,865,474)

           

Operating costs and expenses excluding non-cash
   share based compensation:

         

Cchek™ cancer detection platform

$

759,534

 

$

525,614

CAR-T therapeutics

 

800,791

   

954,853

Patent licensing

 

673,239

 

 

127,146

Total

$

2,233,564

 

$

1,607,613

 

 

 

 

 

 

Operating costs and expenses excluding non-cash
   share based compensation

$

2,233,564

 

$

1,607,613

Plus non-cash share-based compensation

 

2,750,164

 

 

266,973

Total operating costs and expenses

$

4,983,728

 

$

1,874,586


 

 January 31,

2019

 

  October 31,

2018

   

Total assets:

 

 

 

 

 

Cchek™ cancer detection platform

$

2,943,476

 

$

2,545,803

CAR-T therapeutics

 

3,112,658

 

 

2,157,359

Patent licensing

 

414,215

 

 

1,745,380

Total

$

6,470,349

 

$

6,448,542


Operating costs and expenses excluding non-cash share-based compensation is the measurement the chief operating decision-maker uses in managing the enterprise.